Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide

NCT04997317 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Meningioma

Interventions

DRUG: 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)
DRUG: 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4
DRUG: 177Lu-DOTA-JR11 (Phase I/II)

Sponsor

University Hospital, Basel, Switzerland

Collaborators

[object Object]